[1] Nalin DR.Evidence based vaccinology[J].Vaccine,2002,20(11-12):1624-1230.
[2] 徐爱强,宋艳艳,李仁鹏.疫苗研发与免疫实施领域的方法学——循证疫苗学[J].中国计划免疫,2003,9(3):54-58.
[3] Chen W,Zhao Y,Xie X,et al.Safety of a quadrivalent human papillomavirus vaccine in a Phase 3,randomized,double-blind,placebo-controlled clinical trial among Chinese women during 90 months of follow-up[J].Vaccine,2019,37(6):889-897.
[4] 杨泳慧,牛媛娜,由汪洋,等. 2017—2021年60项疫苗临床试验项目伦理初始审查结果分析[J]. 现代疾病预防控制,2023,34(10):760-762,773.
[5] Harmon SHE,Faour D,Macdonald N.National Immunization Technical Advisory Groups (NITAGs):A schema for evaluating and comparing foundation instruments and NITAG operations[J].Medical Law International,2021,21(1):69-98.
[6] 马超,安志杰,李军宏,等.免疫规划循证决策的国内外进展与展望[J].中国疫苗和免疫,2021,27(4):479-484.
[7] O'Leary ST,Yonts AB,Gaviria-Agudelo C,et al.Summer 2023 ACIP update:RSV prevention and updated recommendations on other vaccines[J].Pediatrics,2023,152(5):e2023063955.
[8] Ma C,Rodewald L,An Z,et al.The National Immunization Advisory Committee in China:Roles of national experts in making evidence-based recommendations for immunization[J].China CDC Wkly,2019,1(2):28-30.
[9] 蒋明珠,应晓华,陈雅静.新疫苗纳入国家免疫规划的评价维度及指标分析[J].现代预防医学,2022,49(22):4156-4162.
[10] Ricciardi GW,Toumi M,Weil-olivier C,et al.Comparison of NITAG policies and working processes in selected developed countries[J].Vaccine,2015,33(1):3-11.
[11] Mosina L,Külper-schiek W,Jacques-carroll L,et al.Supporting National Immunization Technical Advisory Groups in the WHO European Region in developing national COVID-19 vaccination recommendations through online communication platform[J].Vaccine,2021,39(45):6595-6600.
[12] 周齐,严鸿伊,张艳丽,等.非劣效性设计临床试验[J].中国卒中杂志,2023,18(6):637-644,636.
[13] Joura EA,Giuliano AR,Iversen OE,et al.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J].N Engl J Med,2015,372(8):711-723.
[14] Andrews N,Stowe J,Kirsebom F,et al.COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant[J]. N Engl J Med,2022,386(16):1532-1546.
[15] World Health Organization. China′s vaccine regulator reaches new WHO rank to ensure safety,quality & effectiveness [EB/OL].(2022-08-23)[2024-1-26]. https://www.who.int/news/item/23-08-2022-china-s-vaccine-regulator-reaches-new-ho-rank-to-ensure-safety--quality---effectiveness. |
